CYP2C19 and transient ischemic attack: The Ticagrelor vs. Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA (CHANCE-2) trial was a multicenter, double-blinded, placebo-controlled, randomized control, superiority trial conducted across 202 centers in China (77).